Skip to main content

Document Preview

Copyright information

© 2019 BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Access to the complete full text

This is a short preview of the document. Your library or institution may give you access to the complete full text for this document in ProQuest.

Explore ProQuest

Full Text
Scholarly Journal

MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes

Drug and Therapeutics Bulletin; London Vol. 57, Iss. 8, (Aug 2019): 117. DOI:10.1136/dtb.2019.000032